
    
      This is an open-label, single-center, randomized, two-period, single and multiple oral dose
      study in 27 healthy female volunteers.

      After a screening period, eligible subjects (n=27) will receive a single oral dose of 5, 15,
      or 45 mg E4 (Period 1). After at least 14-day washout, 18 subjects will continue the study
      (Period 2). They will receive 15 mg E4 once daily for 14 consecutive days.
    
  